(Bloomberg) — There’s no such thing as aspirin resistance, according to a study that suggests a false diagnosis may be unnecessarily raising the number of people given costlier prescription drugs with more side effects to lower their risk of heart attack and stroke.
The report, by University of Pennsylvania researchers, finds the coatings put on aspirin by makers such as Bayer AG mask uptake of the medicine in the blood, leading to false diagnoses that it’s not working, said the study published Tuesday in the journal Circulation. That’s when patients are put on a prescription treatment, such as Bristol-Myers Squibb Co.’s Plavix blood thinner.
Register or login for access to this item and much more
All Employee Benefit News content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access